ALNYLAM PHARMACEUTICALS, INC. Deferred Tax Assets, in Process Research and Development
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Deferred Tax Assets, in Process Research and Development of $12.14 million as of 2018-12-31, per its 10-K filed 2019-02-14.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2019-02-14
- 2018-12-31: Deferred Tax Assets, in Process Research and Development $12.14M.
- 2017-12-31: Deferred Tax Assets, in Process Research and Development $13.16M.
- 2016-12-31: Deferred Tax Assets, in Process Research and Development $18.14M.
- 2015-12-31: Deferred Tax Assets, in Process Research and Development $19.07M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2018-12-31 | $12.14M 10-K · filed 2019-02-14 |
| 2017-12-31 | $13.16M 10-K · filed 2019-02-14 |
| 2016-12-31 | $18.14M 10-K · filed 2018-02-15 |
| 2015-12-31 | $19.07M 10-K · filed 2017-02-15 |
| 2014-12-31 | $19.25M 10-K · filed 2016-02-12 |
| 2013-12-31 | $16.21M 10-K · filed 2015-02-13 |
| 2012-12-31 | $16.10M 10-K · filed 2014-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |